Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Jan 5, 2017
- Reports 2016 Unaudited Year-end Cash and Investments Balance - - Three Clinical Trials Expected to Report Results in 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aes...
Dec 12, 2016
- RT002 injectable appeared to be generally safe and well-tolerated - - RT002 injectable displayed clinically significant impact on cervical dystonia signs and symptoms - - Revance to host conference call at 4:30 pm ET today - NEWARK, Calif.--(BUSINESS WIRE)--...
Dec 7, 2016
- Topline Results of Pivotal Efficacy Trials Anticipated in Fourth Quarter 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications,...
Nov 17, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 28th Annual Piper Jaffray Healthcare Conference. ...
Nov 7, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Jefferies 2016 London Healthcare Conference in London, UK. ...
Nov 3, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the third quarter ended September 30, 2016. Recent Highlights and Upcoming ...
Nov 3, 2016
- Topline Results Expected in 2017 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of a Phase 2 placebo-controlled t...
Oct 24, 2016
- Conference Call Scheduled for Thursday, November 3, 2016 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that th...
Aug 30, 2016
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA. ...
Aug 4, 2016
- Completes Enrollment of Second Cohort of Patients in RT002 Phase 2 Study for Cervical Dystonia - - Updates 2016 Financial Outlook - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin produc...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools